BioXcel Therapeutics reports Q1 EPS ($1.50) vs. ($13.89) last year

Reports revenue $168,000 vs. $582,000 last year. “We are pleased to have achieved this major milestone in our first trial of BXCL501 in the at-home setting,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics (BTAI). “An estimated 23 million episodes of bipolar or schizophrenia-related agitation occur annually at home, yet there are no FDA-approved acute treatment options for patients in this setting. We look forward to a data readout expected in the second half of this year and are excited by the opportunity to expand the market potential of IGALMI and bring this drug to millions of additional patients.”